Compare MBINM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBINM | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.1B |
| IPO Year | 2017 | 1996 |
| Metric | MBINM | VCEL |
|---|---|---|
| Price | $24.92 | $39.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $59.71 |
| AVG Volume (30 Days) | 9.7K | ★ 511.9K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 2.73 | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $21.71 |
| Revenue Next Year | N/A | $16.86 |
| P/E Ratio | $9.13 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $24.00 | $28.95 |
| 52 Week High | $25.96 | $49.32 |
| Indicator | MBINM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 48.55 |
| Support Level | $24.79 | $37.78 |
| Resistance Level | $25.77 | $41.21 |
| Average True Range (ATR) | 0.24 | 1.29 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 30.15 | 47.50 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.